Newsquawk Logo

Merck (MRK) announces Health Canada approval of ENFLONSIA for prevention of RSV in new-borns and infants

Merck's announcement of Health Canada approval for ENFLONSIA marks a significant milestone in its portfolio, positioning the company to tap into the infant vaccination market against RSV.

Newsquawk StaffPublished On the live feed at — 4 more headlines followed before this page went public
Newsquawk headlinesUTC

[WATCH LIVE] : BoE post-policy announcement press conference

SpaceX is considering making its own mobile device, Reuters reports citing sources

Merck (MRK) announces Health Canada approval of ENFLONSIA for prevention of RSV in new-borns and infants

STATEMENT: BoE holds rates at 3.75%, as expected; vote split 5-4 (exp. 7-2; Breeden, Dhingra, Taylor, Ramsden vote for cut to 3.5%)

BoE Forecasts (Feb.): Lowers inflation forecasts across horizon, lowers GDP forecast for Q1 26 and Q1 27

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

This approval could enhance revenue prospects, especially in the European market, and creates potential for further expansion in other regions. Investors may want to monitor how this impacts Merck's competitive position within the pharmaceuticals sector and its share price reaction moving forward.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.